Acute Kidney Injury Is Associated With In-Hospital Mortality of Patients with COVID-19, But Less Common Among Variant B.1.1.7 Positive SARS-Cov-2 Infection
Author:
YAVUZ Demet1ORCID, KADI Nezaket1ORCID, KARAGÖZ ÖZEN Düriye Sıla1ORCID, BİLGİN Melek1ORCID, DEMİRAG Mehmet Derya2ORCID
Affiliation:
1. SAMSUN ÜNİVERSİTESİ, SÜREKLİ EĞİTİM UYGULAMA VE ARAŞTIRMA MERKEZİ 2. SAMSUN UNIVERSITY, SCHOOL OF MEDICINE
Abstract
The aim of this study is to compare the rates of acute kidney injury (AKI) occurence and mortality between hospitalized patients with SARS-CoV-2 infection variant B.1.1.7 positive and negative. 200 hospitalized patients with SARS-CoV-2 infection included in the study. The sociodemographic characteristics of the patients and the laboratory values were obtained retrospectively from the patient files and electronic records. 121 patients with variant B.1.1.7 positive SARS-CoV-2 (group I) and 79 patients with variant B.1.1.7 negative SARS-CoV-2 (group II) included in the study. Acute kidney injury developed at a higher rate in group II patients [15/79 (19%),] compared to group I patients [7/121 (5.8%)] (P=0.004). When 180 patients without chronic kidney disease included in the analysis, acute kidney injury developed in 7 (6.4%) of 110 variant-positive patients, while acute kidney injury developed in 13 (18.6%) of 70 variant-negative patients (P=0.011). It was shown that, AKI development was lower in variant positive patients compared to variant negative patients (OR: 0.32 and 95% CI: 0.12 – 0.88, P=0.027) and age was an independent risk factor for AKI (OR: 1.06 and 95% CI: 1.02 – 1.11, P=0.002). The development of AKI, presence of pre-dialysis chronic kidney disease and age were found to be independent risk factors for mortality [respectively (OR: 6.09 and 95% CI: 1.64 – 22.58, P=0.005), (OR: 5.37 and 95% CI: 1.38 – 20.93, P=0.016), (OR: 1.06 and 95% CI: 1.02 – 1.11, P=0.005)].
Publisher
Ordu University
Reference40 articles.
1. Betjes MG. 2013. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol, 9(5): 255-265. 2. Callaway E. 2021. Heavily mutated Omicron variant puts scientists on alert. Nature, 600(7887): 21. 3. Carriazo S, Kanbay M, Ortiz A. 2020. Kidney disease and electrolytes in COVID-19: more than meets the eye. Clin Kidney J, 13(3): 274-280. 4. Chavda VP, Kapadia C, Soni S, Prajapati R, Chauhan SC, Yallapu MM, Apostolopoulos V. 2022. A global picture: therapeutic perspectives for COVID-19. Immunotherapy, 14(5): 351-371. 5. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, Tang C, Sang L, Liu J, Ni Z, Hu Y, Liu L, Shan H, Lei C, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, Zhu S, Liu X,
|
|